SEARCH

Current Edition

FDA

FDA rejects Insys opioid pain spray

Insys Therapeutics said Friday that the Food and Drug Administration issued it a Complete Response Letter rejecting the company’s New Drug Application for Buvaya. The …

Continue Reading →
$58M

Nuance enters $58 M deal for non-opioid pain treatment in China

EXPAREL is a non-opioid option for achieving long-lasting pain control after surgery via infiltration into the surgical site or administration as an interscalene brachial plexus …

Continue Reading →